MEDIORG Stock Overview
Engages in the developing, manufacturing, and distribution of a range of pharmaceutical dosage in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Medicamen Organics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹65.60 |
| 52 Week High | ₹159.40 |
| 52 Week Low | ₹61.00 |
| Beta | 0 |
| 11 Month Change | -22.37% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDIORG | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.08% | 1.2% | -1.2% |
| 1Y | n/a | 59.0% | 37.9% |
Return vs Industry: Insufficient data to determine how MEDIORG performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MEDIORG performed against the Indian Market.
Price Volatility
| MEDIORG volatility | |
|---|---|
| MEDIORG Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: MEDIORG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MEDIORG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 62 | Bal Gupta | www.medicamenorganics.com |
Medicamen Organics Limited engages in the developing, manufacturing, and distribution of a range of pharmaceutical dosage in India and internationally. The company offers anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental cure, proton pump inhibitor, anti-protozoal, anti-histamine, anti-hypertensive, anti-lipidemic, anti-parasitic, multivitamin, multimineral, and non-steroidal anti-inflammatory drugs in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. It markets its products to for government and private institutions as contract manufacturer/third party manufacturer; and private pharma companies through third party distributors.
Medicamen Organics Limited Fundamentals Summary
| MEDIORG fundamental statistics | |
|---|---|
| Market cap | ₹767.52m |
| Earnings (TTM) | ₹24.04m |
| Revenue (TTM) | ₹252.72m |
31.9x
P/E Ratio3.0x
P/S RatioIs MEDIORG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDIORG income statement (TTM) | |
|---|---|
| Revenue | ₹252.72m |
| Cost of Revenue | ₹157.99m |
| Gross Profit | ₹94.73m |
| Other Expenses | ₹70.69m |
| Earnings | ₹24.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.05 |
| Gross Margin | 37.49% |
| Net Profit Margin | 9.51% |
| Debt/Equity Ratio | 83.4% |
How did MEDIORG perform over the long term?
See historical performance and comparison